EZH2 and cancer: Recently, through a pruning strategy applied on known indazole-containing EZH2 inhibitors (EZH2i) (such as EPZ005687 and UNC1999, Fig. 1), our group reported the novel pyrazole-based EZH2i MC3629 (Fig. 1), potent at low micromolar doses and able to reduce H3K27me3 levels, to arrest cell proliferation and to induce autophagy in a panel of cancer cell lines (SK-N-BE neuroblastoma, MDA-MB231 breast cancer, and K562 leukaemia cells) [17].